Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transcranial Doppler

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Transcranial Doppler. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2017-000868-15 Sponsor Protocol Number: P001151 Start Date*: 2019-01-15
    Sponsor Name:Medical Center -University of Freiburg
    Full Title: Stereotactic Cisternal Lavage in Patients with Aneurysmal Subarachnoid Hemorrhage with Urokinase and Nimodipine for the Prevention of Secondary Brain Injury. A Randomized Controlled Trial.
    Medical condition: Aneurysmal Subarachnoid Hemorrhage (aSAH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002721-18 Sponsor Protocol Number: AC-054-203 Start Date*: 2016-02-17
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A prospective, multi-center, open-label, single-arm, Phase 2 study to assess the efficacy and safety of clazosentan in reversing angiographically-confirmed cerebral vasospasm in adult subjects with...
    Medical condition: Aneurysmal subarachnoid hemorrhage (aSAH); cerebral vasospasm
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10047164 Vasospasm cerebral LLT
    19.1 100000004863 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000331-63 Sponsor Protocol Number: HGB-210 Start Date*: 2021-02-09
    Sponsor Name: bluebird bio, Inc.
    Full Title: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000201-24 Sponsor Protocol Number: O3Cardio Start Date*: 2018-08-01
    Sponsor Name:Bernardino Clavo - Hospital Dr. Negrín
    Full Title: Effectiveness and cost-effectiveness of Ozone therapy in patients with ischemic heart disease refractory to medical and surgical treatment: Randomized, triple-blind clinical trial.
    Medical condition: Ischemic heart disease refractory to medical and surgical treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    20.0 100000004849 10055224 Cardiac ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003444-24 Sponsor Protocol Number: 1160.189 Start Date*: 2014-11-21
    Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
    Full Title: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acet...
    Medical condition: A study to compare dabigatran etexilate to acetylsalicylic acid in preventing recurrent stroke for patients that already had a stroke caused by an embolus (clot). Despite testing, it is unknown wh...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10067167 Cerebellar embolism PT
    18.1 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    18.1 10029205 - Nervous system disorders 10060839 Embolic cerebral infarction PT
    18.1 10029205 - Nervous system disorders 10074422 Brain stem embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) BE (Completed) AT (Completed) HU (Completed) IT (Completed) SE (Completed) SI (Completed) ES (Completed) CZ (Completed) SK (Completed) PL (Completed) HR (Completed) GR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001747-12 Sponsor Protocol Number: CSEG101B2201 Start Date*: 2019-05-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups o...
    Medical condition: Sickle Cell Disease with Vaso-Occlusive Crisis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    20.1 10010331 - Congenital, familial and genetic disorders 10002077 Anaemia sickle cell LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Restarted) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003959-22 Sponsor Protocol Number: CV006-004 Start Date*: 2016-09-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS-986141 For the Prevention of Recurrent Brain Infarction in Subjects receiving acet...
    Medical condition: Recurrent Brain Infarction in Subjects receiving acetylsalicyl acid (ASA) following Acute Ischemic Stroke or Transient Ischemic Attack
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    19.0 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004568-37 Sponsor Protocol Number: INV543 Start Date*: 2018-11-30
    Sponsor Name:Nova Laboratories Limited
    Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia
    Medical condition: Sickle Cell Anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003572-23 Sponsor Protocol Number: GCP#01.01.030 Start Date*: 2017-12-27
    Sponsor Name:Gamida Cell Ltd
    Full Title: Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies
    Medical condition: Hemoglobinopathies
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10054658 Thalassemia LLT
    18.0 100000004850 10040645 Sickle cell disease NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005876-21 Sponsor Protocol Number: DANOHCA-001 Start Date*: 2022-07-08
    Sponsor Name:Department of Cardiology, Copenhagen University Hospital, Rigshospitalet
    Full Title: The Danish Out-of-Hospital Cardiac Arrest study (DANOHCA)
    Medical condition: We will investigate the efficacy of four interventions (two pharmaceutical) for reducing mortality and organ damage in patients resuscitated after out-of-hospital cardiac arrest.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003109 Arrest cardiac LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004209-15 Sponsor Protocol Number: GBT440-007 Start Date*: 2019-01-08
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-001320-19 Sponsor Protocol Number: CTX001-121 Start Date*: 2018-12-05
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sick...
    Medical condition: Severe Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002764-27 Sponsor Protocol Number: NILVAD2012 Start Date*: 2013-02-04
    Sponsor Name:St James's Hospital
    Full Title: A European multicenre double-blind placebo controlled phase III trial of nilvadipine in mild to moderate Alzheimer's disease.
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) GR (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 15:29:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA